仁度生物
(688193)
| 流通市值：12.86亿 | | | 总市值：17.00亿 |
| 流通股本：3025.76万 | | | 总股本：4000.00万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 130,643,714.19 | 86,680,181.82 | 44,815,148.38 | 164,412,273.1 |
| 营业收入 | 130,643,714.19 | 86,680,181.82 | 44,815,148.38 | 164,412,273.1 |
| 二、营业总成本 | 135,834,212.99 | 88,418,762.35 | 43,739,944.96 | 182,287,512.91 |
| 营业成本 | 25,620,656.61 | 16,421,995.35 | 8,713,080.04 | 30,610,426.46 |
| 税金及附加 | 739,806.32 | 493,799.48 | 244,779.04 | 965,105.53 |
| 销售费用 | 63,481,069.09 | 41,477,629.2 | 20,257,085.34 | 90,945,387.18 |
| 管理费用 | 21,655,552.53 | 13,991,470.76 | 7,223,829.28 | 26,768,089.51 |
| 研发费用 | 29,996,309.8 | 20,681,562.91 | 10,176,017.01 | 41,136,167.45 |
| 财务费用 | -5,659,181.36 | -4,647,695.35 | -2,874,845.75 | -8,137,663.22 |
| 其中:利息费用 | 188,569.1 | 161,839.68 | 110,231.74 | 431,196.7 |
| 其中:利息收入 | 5,951,800.48 | 4,838,739.27 | 2,555,151.45 | 8,724,874.07 |
| 加:公允价值变动收益 | 3,661,988.88 | 1,557,974.97 | 620,808.32 | 661,635.37 |
| 加:投资收益 | 3,618,280.83 | 2,313,496.11 | 974,191.98 | 6,923,912.48 |
| 资产处置收益 | - | - | - | -53,511 |
| 资产减值损失(新) | -1,925,192.93 | -1,133,262.76 | -357,326.04 | -1,275,623.92 |
| 信用减值损失(新) | -118,226.41 | -268,509.67 | -425,494.71 | -629,909.31 |
| 其他收益 | 4,456,961.17 | 3,193,437.95 | 1,486,340.57 | 17,690,949.26 |
| 营业利润平衡项目 | 0 | 0 | -0.01 | 0 |
| 四、营业利润 | 4,503,312.74 | 3,924,556.07 | 3,373,723.53 | 5,442,213.07 |
| 加:营业外收入 | 177,875.94 | 33,030.83 | 33,030.83 | 135,382.24 |
| 减:营业外支出 | 193,102.94 | 140,763.23 | 33,612.63 | 815,064.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 4,488,085.74 | 3,816,823.67 | 3,373,141.73 | 4,762,531.15 |
| 减:所得税费用 | -183,111.19 | -513,987.5 | -330,766.09 | -3,496,765.43 |
| 六、净利润 | 4,671,196.93 | 4,330,811.17 | 3,703,907.82 | 8,259,296.58 |
| 持续经营净利润 | 4,671,196.93 | 4,330,811.17 | 3,703,907.82 | 8,259,296.58 |
| 归属于母公司股东的净利润 | 4,671,196.93 | 4,330,811.17 | 3,703,907.82 | 8,259,296.58 |
| (一)基本每股收益 | 0.12 | 0.12 | 0.09 | 0.21 |
| (二)稀释每股收益 | 0.12 | 0.12 | 0.09 | 0.24 |
| 八、其他综合收益 | -414,675.12 | 244,721.56 | 68,675.78 | 621,345.98 |
| 归属于母公司股东的其他综合收益 | -414,675.12 | 244,721.56 | 68,675.78 | 621,345.98 |
| 九、综合收益总额 | 4,256,521.81 | 4,575,532.73 | 3,772,583.6 | 8,880,642.56 |
| 归属于母公司股东的综合收益总额 | 4,256,521.81 | 4,575,532.73 | 3,772,583.6 | 8,880,642.56 |
| 公告日期 | 2024-10-30 | 2024-08-30 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |